Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
102 hedge funds and large institutions have $845M invested in Spark Therapeutics, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 21 reducing their positions, and 11 closing their positions.
219% more call options, than puts
Call options by funds: $9.82M | Put options by funds: $3.08M
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
105% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 21
36% more capital invested
Capital invested by funds: $623M → $845M (+$221M)
13% more funds holding
Funds holding: 90 → 102 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.7M |
| 2 |
JP Morgan Chase
New York
|
+$28.4M |
| 3 |
ClearBridge Investments
New York
|
+$20.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$11.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.73M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$7.92M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$6.04M |
| 5 |
BG
BlackRock Group
London,
United Kingdom
|
-$4.75M |
ONCE Hedge Fund Activity: Q4 2015 in Review
102 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q4 2015, worth a combined $845M — up 36% from $623M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ONCE positions and 11 closed out — a net gain of 12 holders — while 43 added to existing stakes and 21 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $41.7M. The largest seller was Highland Capital Management (Texas), exiting entirely with an estimated $11.1M sold.
- 102 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q4 2015, up from 90 in Q3 2015.
- Funds reported $845M of Spark Therapeutics, Inc. Common Stock stock for Q4 2015, up 36% quarter-over-quarter.
- 23 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q4 2015 and 11 closed out, a net change of +12 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q4 2015 was T. Rowe Price Associates, an estimated $41.7M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q4 2015 was Highland Capital Management (Texas), an estimated $11.1M sold.
Based on aggregated 13F filings for Q4 2015.